enobosarm + semaglutide

Enobosarm + semaglutide is a combination therapy being developed for obesity treatment, particularly in older adults. Enobosarm is an oral selective androgen receptor modulator (SARM) that selectively targets androgen receptors in skeletal muscle to preserve lean mass, while semaglutide (Wegovy) is a GLP-1 receptor agonist that promotes weight loss. The combination aims to make weight reduction more tissue selective for fat loss while preserving muscle mass and physical function. In Phase 2b clinical trials, this combination demonstrated a 71% reduction in lean mass loss compared to semaglutide alone, with the enobosarm 3mg dose showing >99% preservation of lean mass. Additionally, the combination enhanced fat loss, with 90.6-99.1% of weight loss coming from fat rather than muscle, compared to 68% with semaglutide alone.

Other names

enobosarm + GLP-1 receptor agonistenobosarm plus semaglutideenobosarm + GLP-1 RAostarineenobosarm + Wegovy